PDF herunterladen
Semin Neurol 2019; 39(05): 596-607
DOI: 10.1055/s-0039-1693008
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Jeffrey Shije
1   Peripheral Neuropathy Center, Neurological Institute, Columbia University, New York, New York
,
Thomas H. Brannagan III
1   Peripheral Neuropathy Center, Neurological Institute, Columbia University, New York, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. Oktober 2019 (online)

    Lizenzen und Reprints

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a relatively common autoimmune disorder affecting the peripheral nerves and nerve roots, often causing progressive or recurrent weakness with diminished reflexes. Electrodiagnostic (EDx) studies, cerebral spinal fluid (CSF) analysis, and nerve biopsy may help provide supportive evidence for the diagnosis. Most cases have a favorable response to one of the three first-line treatments: corticosteroids, IV immunoglobulin (IVIG) and plasmapheresis. Responses to these treatments may vary among individual patients. There is evidence that a small percentage of CIDP patients with IgG class 4 (IgG4) autoantibodies to paranodal proteins have characteristic clinical features and poorer response to IVIG. Chemotherapy and other immunomodulatory agents, as well as hematopoietic stem cell transplantation, may be considered in refractory cases. The degree of disability varies, and most patients require ongoing treatment to maintain stable disease, although long-term remission or cure may be achieved in some patients.

Keywords

chronic inflammatory demyelinating polyradiculoneuropathy - CIDP - inflammatory neuropathy
 

  • References

  • 1 Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958; 81 (02) 157-192
    CrossrefPubMedGoogle Scholar
  • 2 Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50 (11) 621-637
    PubMedGoogle Scholar
  • 3 McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110 (Pt 6): 1617-1630
    CrossrefPubMedGoogle Scholar
  • 4 Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46 (08) 878-884
    CrossrefPubMedGoogle Scholar
  • 5 Hattori N, Misu K, Koike H. , et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184 (01) 57-63
    CrossrefPubMedGoogle Scholar
  • 6 Querol L, Nogales-Gadea G, Rojas-Garcia R. , et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014; 82 (10) 879-886
    CrossrefPubMedGoogle Scholar
  • 7 Ogata H, Yamasaki R, Hiwatashi A. , et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015; 2 (10) 960-971
    CrossrefPubMedGoogle Scholar
  • 8 Devaux JJ, Miura Y, Fukami Y. , et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86 (09) 800-807
    CrossrefPubMedGoogle Scholar
  • 9 Kadoya M, Kaida K, Koike H. , et al. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 2016; 301: 16-22
    CrossrefPubMedGoogle Scholar
  • 10 Doppler K, Appeltshauser L, Wilhelmi K. , et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 2015; 86 (07) 720-728
    CrossrefPubMedGoogle Scholar
  • 11 Miura Y, Devaux JJ, Fukami Y. , et al; CNTN1-CIDP Study Group. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015; 138 (Pt 6): 1484-1491
    CrossrefPubMedGoogle Scholar
  • 12 Henderson RD, Sandroni P, Wijdicks EFM. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol 2005; 252 (10) 1235-1237
    CrossrefPubMedGoogle Scholar
  • 13 Macia F, Le Masson G, Rouanet-Larriviere M. , et al. A prospective evaluation of phrenic nerve conduction in multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2003; 28 (03) 319-323
    CrossrefPubMedGoogle Scholar
  • 14 Ingall TJ, McLeod JG, Tamura N. Autonomic function and unmyelinated fibers in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1990; 13 (01) 70-76
    CrossrefPubMedGoogle Scholar
  • 15 Lyu R-K, Tang L-M, Wu Y-R, Chen S-T. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 26 (05) 669-672
    CrossrefPubMedGoogle Scholar
  • 16 Stamboulis E, Katsaros N, Koutsis G, Iakovidou H, Giannakopoulou A, Simintzi I. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2006; 33 (01) 78-84
    CrossrefPubMedGoogle Scholar
  • 17 Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 50 (04) 1179-1182
    CrossrefPubMedGoogle Scholar
  • 18 Figueroa JJ, Dyck PJB, Laughlin RS. , et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78 (10) 702-708
    CrossrefPubMedGoogle Scholar
  • 19 Ruts L, Drenthen J, Jacobs BC, van Doorn PA. ; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74 (21) 1680-1686
    CrossrefPubMedGoogle Scholar
  • 20 Laughlin RS, Dyck PJB, Melton III LJ, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73 (01) 39-45
    CrossrefPubMedGoogle Scholar
  • 21 Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66 (05) 677-680
    CrossrefPubMedGoogle Scholar
  • 22 Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 23 Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49 (03) 169-174
    CrossrefPubMedGoogle Scholar
  • 24 Chiò A, Cocito D, Bottacchi E. , et al; PARCIDP. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78 (12) 1349-1353
    CrossrefPubMedGoogle Scholar
  • 25 McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46 (06) 910-913
    CrossrefPubMedGoogle Scholar
  • 26 Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39 (04) 432-438
    CrossrefPubMedGoogle Scholar
  • 27 Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21 (01) 28-33
    CrossrefPubMedGoogle Scholar
  • 28 Larsen JP, Kvåle G, Nyland H. Epidemiology of the Guillain-Barré syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985; 71 (01) 43-47
    PubMedGoogle Scholar
  • 29 Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996; 19 (04) 474-487
    CrossrefPubMedGoogle Scholar
  • 30 Schneider-Hohendorf T, Schwab N, Uçeyler N, Göbel K, Sommer C, Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78 (06) 402-408
    CrossrefPubMedGoogle Scholar
  • 31 Misawa S, Kuwabara S, Mori M, Kawaguchi N, Yoshiyama Y, Hattori T. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 2001; 56 (05) 666-669
    CrossrefPubMedGoogle Scholar
  • 32 Beppu M, Sawai S, Misawa S. , et al. Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2015; 279: 7-10
    CrossrefPubMedGoogle Scholar
  • 33 Rentzos M, Angeli AV, Rombos A. , et al. Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients. Neurol Res 2012; 34 (09) 842-846
    CrossrefPubMedGoogle Scholar
  • 34 Mei F-J, Ishizu T, Murai H. , et al. Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J Neurol Sci 2005; 228 (01) 75-85
    CrossrefPubMedGoogle Scholar
  • 35 Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci 1999; 163 (01) 47-52
    CrossrefPubMedGoogle Scholar
  • 36 Salomon B, Rhee L, Bour-Jordan H. , et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001; 194 (05) 677-684
    CrossrefPubMedGoogle Scholar
  • 37 Harvey GK, Pollard JD, Schindhelm K, Antony J. Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci 1987; 81 (2-3): 215-225
    CrossrefPubMedGoogle Scholar
  • 38 McCombe PA, van der Kreek SA, Pender MP. The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. J Neuroimmunol 1990; 28 (02) 131-140
    CrossrefPubMedGoogle Scholar
  • 39 Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50 (03) 286-292
    CrossrefPubMedGoogle Scholar
  • 40 Meléndez-Vásquez C, Redford J, Choudhary PP. , et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997; 73 (1-2): 124-134
    CrossrefPubMedGoogle Scholar
  • 41 Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000; 104 (02) 139-146
    CrossrefPubMedGoogle Scholar
  • 42 Sanvito L, Makowska A, Mahdi-Rogers M. , et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2009; 80 (03) 333-338
    CrossrefPubMedGoogle Scholar
  • 43 Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RA. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46 (1-2): 245-251
    CrossrefPubMedGoogle Scholar
  • 44 Vural A, Doppler K, Meinl E. Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol 2018; 9: 1029
    Google Scholar
  • 45 Albers JW, Kelly Jr JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12 (06) 435-451
    CrossrefPubMedGoogle Scholar
  • 46 Cornblath DR, Asbury AK, Albers JW. , et al. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41 (05) 617-618
    CrossrefPubMedGoogle Scholar
  • 47 Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991; 14 (10) 968-976
    CrossrefPubMedGoogle Scholar
  • 48 Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24 (03) 311-324
    CrossrefPubMedGoogle Scholar
  • 49 Latov N. Diagnosis of CIDP. Neurology 2002; 59 (12) (Suppl. 06) S2-S6
    PubMedGoogle Scholar
  • 50 Nicolas G, Maisonobe T, Le Forestier N, Léger J-M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 25 (01) 26-30
    CrossrefPubMedGoogle Scholar
  • 51 Hughes R, Bensa S, Willison H. , et al; Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50 (02) 195-201
    CrossrefPubMedGoogle Scholar
  • 52 Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 59 (10) 1526-1532
    CrossrefPubMedGoogle Scholar
  • 53 Magda P, Latov N, Brannagan III TH, Weimer LH, Chin RL, Sander HW. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2003; 60 (12) 1755-1759
    CrossrefPubMedGoogle Scholar
  • 54 Berger AR, Bradley WG, Brannagan TH. , et al; Neuropathy Association, Medical Advisory Committee. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2003; 8 (04) 282-284
    CrossrefPubMedGoogle Scholar
  • 55 Van Schaik IN, Léger JM, Nobile-Orazio E. , et al; Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 2010; 15 (04) 295-301
    CrossrefPubMedGoogle Scholar
  • 56 Breiner A, Brannagan III TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014; 50 (01) 40-46
    CrossrefPubMedGoogle Scholar
  • 57 Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32 (09) 958-964
    CrossrefPubMedGoogle Scholar
  • 58 Viala K, Renié L, Maisonobe T. , et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127 (Pt 9): 2010-2017
    CrossrefPubMedGoogle Scholar
  • 59 Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54 (03) 615-620
    CrossrefPubMedGoogle Scholar
  • 60 Leitch MM, Sherman WH, Brannagan III TH. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide. Muscle Nerve 2013; 47 (02) 292-296
    CrossrefPubMedGoogle Scholar
  • 61 Gable KL, Afshari Z, Sufit RL, Allen JA. Distal acquired demyelinating symmetric neuropathy after vaccination. J Clin Neuromuscul Dis 2013; 14 (03) 117-122
    CrossrefPubMedGoogle Scholar
  • 62 Dyck PJ, Dyck PJB. Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 2000; 355 (9212): 1293-1294
    CrossrefPubMedGoogle Scholar
  • 63 Larue S, Bombelli F, Viala K. , et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011; 18 (06) 899-905
    CrossrefPubMedGoogle Scholar
  • 64 Oh SJ, Joy JL, Kuruoglu R. “Chronic sensory demyelinating neuropathy”: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992; 55 (08) 677-680
    CrossrefPubMedGoogle Scholar
  • 65 Chin RL, Latov N, Sander HW. , et al. Sensory CIDP presenting as cryptogenic sensory polyneuropathy. J Peripher Nerv Syst 2004; 9 (03) 132-137
    CrossrefPubMedGoogle Scholar
  • 66 Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as “chronic sensory demyelinating polyneuropathy”. Muscle Nerve 1995; 18 (04) 440-444
    CrossrefPubMedGoogle Scholar
  • 67 van Dijk GW, Notermans NC, Franssen H, Wokke JHJ. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol 1999; 246 (12) 1134-1139
    CrossrefPubMedGoogle Scholar
  • 68 Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004; 63 (09) 1662-1669
    CrossrefPubMedGoogle Scholar
  • 69 Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002; 59 (05) 758-765
    CrossrefPubMedGoogle Scholar
  • 70 Chiò A, Plano F, Calvo A, Leone M, Mutani R, Cocito D. ; Piemonte and Valle D'Aosta Registry for CIDP (PARCIDP). Comorbidity between CIDP and diabetes mellitus: only a matter of chance?. Eur J Neurol 2009; 16 (06) 752-754
    CrossrefPubMedGoogle Scholar
  • 71 Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000; 23 (01) 37-43
    CrossrefPubMedGoogle Scholar
  • 72 Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 2009; 80 (01) 70-73
    CrossrefPubMedGoogle Scholar
  • 73 Cornblath DR. Treatment of the neuromuscular complications of human immunodeficiency virus infection. Ann Neurol 1988; 23 (Suppl): S88-S91
    CrossrefPubMedGoogle Scholar
  • 74 Ferrari S, Vento S, Monaco S. , et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 2006; 81 (02) 213-219
    CrossrefPubMedGoogle Scholar
  • 75 Przedborski S, Liesnard C, Voordecker P. , et al. Inflammatory demyelinating polyradiculoneuropathy associated with human immunodeficiency virus infection. J Neurol 1988; 235 (06) 359-361
    CrossrefPubMedGoogle Scholar
  • 76 Moodley K, Bill PLA, Patel VB. A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients. Neurol Neuroimmunol Neuroinflamm 2016; 4 (02) e315
    PubMedGoogle Scholar
  • 77 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48 (02) 321-328
    CrossrefPubMedGoogle Scholar
  • 78 Nobile-Orazio E, Latov N, Hays AP. , et al. Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 1984; 34 (02) 218-221
    CrossrefPubMedGoogle Scholar
  • 79 Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988; 3 (04) 301-332
    PubMedGoogle Scholar
  • 80 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000; 123 (Pt 4): 710-717
    CrossrefPubMedGoogle Scholar
  • 81 Renaud S, Gregor M, Fuhr P. , et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27 (05) 611-615
    CrossrefPubMedGoogle Scholar
  • 82 Nobile-Orazio E, Manfredini E, Carpo M. , et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36 (03) 416-424
    CrossrefPubMedGoogle Scholar
  • 83 Garcia-Santibanez R, Zaidman CM, Sommerville RB. , et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). J Neurol 2018; 265 (06) 1402-1409
    CrossrefPubMedGoogle Scholar
  • 84 Carpo M, Meucci N, Allaria S. , et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci 2000; 176 (02) 144-150
    CrossrefPubMedGoogle Scholar
  • 85 Guo X, Qin X, Zhang Y, Huang C, Yu G. Electrophysiological features of POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Clin Neurosci 2014; 21 (04) 587-590
    CrossrefPubMedGoogle Scholar
  • 86 Lozeron P, Mariani L-L, Dodet P. , et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 2018; 91 (02) e143-e152
    CrossrefPubMedGoogle Scholar
  • 87 Bird SJ, Sladky JT. Corticosteroid-responsive dominantly inherited neuropathy in childhood. Neurology 1991; 41 (03) 437-439
    CrossrefPubMedGoogle Scholar
  • 88 Donaghy M, Sisodiya SM, Kennett R, McDonald B, Haites N, Bell C. Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. J Neurol Neurosurg Psychiatry 2000; 69 (06) 799-805
    CrossrefPubMedGoogle Scholar
  • 89 Ginsberg L, Malik O, Kenton AR. , et al. Coexistent hereditary and inflammatory neuropathy. Brain 2004; 127 (Pt 1): 193-202
    CrossrefPubMedGoogle Scholar
  • 90 Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982; 32 (06) 592-596
    CrossrefPubMedGoogle Scholar
  • 91 Rechthand E, Cornblath DR, Stern BJ, Meyerhoff JO. Chronic demyelinating polyneuropathy in systemic lupus erythematosus. Neurology 1984; 34 (10) 1375-1377
    CrossrefPubMedGoogle Scholar
  • 92 Gondim FAA, Brannagan III TH, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 2005; 128 (Pt 4): 867-879
    CrossrefPubMedGoogle Scholar
  • 93 Wong AHY, Kokubun N, Fukami Y, Miyaji K, Yuki N. Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy. J Peripher Nerv Syst 2015; 20 (01) 63-66
    CrossrefPubMedGoogle Scholar
  • 94 Echaniz-Laguna A, de Séze J, Chanson J-B. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. J Neurol Neurosurg Psychiatry 2012; 83 (07) 699-705
    CrossrefPubMedGoogle Scholar
  • 95 Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve 2018; 57 (06) 875-883
    CrossrefPubMedGoogle Scholar
  • 96 Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-α antagonists. Muscle Nerve 2010; 41 (05) 723-727
    CrossrefPubMedGoogle Scholar
  • 97 Kao JC, Liao B, Markovic SN. , et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 2017; 74 (10) 1216-1222
    CrossrefPubMedGoogle Scholar
  • 98 Kolb NA, Trevino CR, Waheed W. , et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve 2018; 58: 10-22
    CrossrefPubMedGoogle Scholar
  • 99 Mathis S, Magy L, Diallo L, Boukhris S, Vallat J-M. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 45 (01) 26-31
    CrossrefPubMedGoogle Scholar
  • 100 Dyck PJ, O'Brien PC, Oviatt KF. , et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11 (02) 136-141
    CrossrefPubMedGoogle Scholar
  • 101 Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62 (02) 249-254
    CrossrefPubMedGoogle Scholar
  • 102 Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008; 65 (11) 1460-1464
    CrossrefPubMedGoogle Scholar
  • 103 van Schaik IN, Eftimov F, van Doorn PA. , et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9 (03) 245-253
    CrossrefPubMedGoogle Scholar
  • 104 Nobile-Orazio E, Cocito D, Jann S. , et al; IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11 (06) 493-502
    CrossrefPubMedGoogle Scholar
  • 105 Mendell JR, Barohn RJ, Freimer ML. , et al; Working Group on Peripheral Neuropathy. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56 (04) 445-449
    CrossrefPubMedGoogle Scholar
  • 106 Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119 (Pt 4): 1067-1077
    CrossrefPubMedGoogle Scholar
  • 107 Hughes RAC, Donofrio P, Bril V. , et al; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7 (02) 136-144
    CrossrefPubMedGoogle Scholar
  • 108 Kaplan A, Brannagan III TH. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2017; 55 (04) 476-482
    CrossrefPubMedGoogle Scholar
  • 109 Brannagan III TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47 (03) 674-677
    CrossrefPubMedGoogle Scholar
  • 110 Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29 (03) 173-184
    CrossrefPubMedGoogle Scholar
  • 111 Kuitwaard K, van den Berg LH, Vermeulen M. , et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010; 81 (12) 1374-1379
    CrossrefPubMedGoogle Scholar
  • 112 Gallia F, Balducci C, Nobile-Orazio E. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies. J Peripher Nerv Syst 2016; 21 (02) 82-84
    CrossrefPubMedGoogle Scholar
  • 113 Markvardsen LH, Sindrup SH, Christiansen I, Olsen NK, Jakobsen J, Andersen H. ; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol 2017; 24 (02) 412-418
    CrossrefPubMedGoogle Scholar
  • 114 Markvardsen LH, Debost J-C, Harbo T. , et al; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013; 20 (05) 836-842
    CrossrefPubMedGoogle Scholar
  • 115 Markvardsen LH, Harbo T, Sindrup SH, Christiansen I, Andersen H, Jakobsen J. ; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2014; 21 (12) 1465-1470
    CrossrefPubMedGoogle Scholar
  • 116 van Schaik IN, Bril V, van Geloven N. , et al; PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17 (01) 35-46
    CrossrefPubMedGoogle Scholar
  • 117 Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis. Muscle Nerve 2017; 55 (06) 802-809
    CrossrefPubMedGoogle Scholar
  • 118 Dyck PJ, Litchy WJ, Kratz KM. , et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36 (06) 838-845
    CrossrefPubMedGoogle Scholar
  • 119 Hahn AF, Bolton CF, Pillay N. , et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119 (Pt 4): 1055-1066
    CrossrefPubMedGoogle Scholar
  • 120 Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2017; 11: CD002062
    PubMedGoogle Scholar
  • 121 Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; 12 (12) CD001797
    PubMedGoogle Scholar
  • 122 Mehndiratta MM, Hughes RAC, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2015; 8 (08) CD003906
    PubMedGoogle Scholar
  • 123 Cocito D, Paolasso I, Antonini G. , et al; Italian Network for CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17 (02) 289-294
    CrossrefPubMedGoogle Scholar
  • 124 Cocito D, Grimaldi S, Paolasso I. , et al; Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011; 18 (12) 1417-1421
    CrossrefPubMedGoogle Scholar
  • 125 Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry 2010; 81 (06) 634-636
    CrossrefPubMedGoogle Scholar
  • 126 Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006; 77 (04) 544-547
    CrossrefPubMedGoogle Scholar
  • 127 Gladstone DE, Prestrud AA, Brannagan III TH. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005; 10 (01) 11-16
    CrossrefPubMedGoogle Scholar
  • 128 Matsuda M, Hoshi K, Gono T, Morita H, Ikeda S. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 224 (1-2): 29-35
    CrossrefPubMedGoogle Scholar
  • 129 Odaka M, Tatsumoto M, Susuki K, Hirata K, Yuki N. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005; 76 (08) 1115-1120
    CrossrefPubMedGoogle Scholar
  • 130 Gorson KC, Allam G, Simovic D, Ropper AH. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997; 48 (03) 777-780
    CrossrefPubMedGoogle Scholar
  • 131 Pavesi G, Cattaneo L, Marbini A, Gemignani F, Mancia D. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002; 249 (06) 777-779
    CrossrefPubMedGoogle Scholar
  • 132 Vallat J-M, Hahn AF, Léger J-M. , et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003; 60 (08) (Suppl. 03) S23-S28
    CrossrefPubMedGoogle Scholar
  • 133 Benedetti L, Briani C, Franciotta D. , et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82 (03) 306-308
    CrossrefPubMedGoogle Scholar
  • 134 Roux T, Debs R, Maisonobe T. , et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst 2018; 23 (04) 235-240
    CrossrefPubMedGoogle Scholar
  • 135 Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35 (08) 1173-1176
    CrossrefPubMedGoogle Scholar
  • 136 Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53 (01) 57-61
    CrossrefPubMedGoogle Scholar
  • 137 Hughes RAC, Gorson KC, Cros D. , et al; Avonex CIDP Study Group. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74 (08) 651-657
    CrossrefPubMedGoogle Scholar
  • 138 Mahdi-Rogers M, Rutterford C, Hughes RAC. , et al; RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8 (02) 158-164
    CrossrefPubMedGoogle Scholar
  • 139 Hughes R, Dalakas MC, Merkies I. , et al; FORCIDP Trial Investigators. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol 2018; 17 (08) 689-698
    CrossrefPubMedGoogle Scholar
  • 140 Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2017; 5: CD003280
    PubMedGoogle Scholar
  • 141 Marsh EA, Hirst CL, Llewelyn JG. , et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257 (06) 913-919
    CrossrefPubMedGoogle Scholar
  • 142 Ahlmén J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998; 30 (08) 4194
    CrossrefPubMedGoogle Scholar
  • 143 Renard D, Gauthier T, Venetz J-P, Buclin T, Kuntzer T. Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J 2012; 5 (04) 323-326
    CrossrefPubMedGoogle Scholar
  • 144 Chin RL, Sherman WH, Sander HW, Hays AP, Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003; 210 (1-2): 19-21
    CrossrefPubMedGoogle Scholar
  • 145 Oyama Y, Sufit R, Loh Y. , et al. Nonmyeloablative autologous hematopoietic stem celltransplantation for refractory CIDP. Neurology 2007; 69 (18) 1802-1803
    CrossrefPubMedGoogle Scholar
  • 146 Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72 (01) 127-128
    CrossrefPubMedGoogle Scholar
  • 147 Vermeulen M, van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry 2007; 78 (10) 1154
    CrossrefPubMedGoogle Scholar
  • 148 Press R, Askmark H, Svenningsson A. , et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry 2014; 85 (06) 618-624
    CrossrefPubMedGoogle Scholar
  • 149 Garg N, Park SB, Yiannikas C. , et al. Neurofascin-155 IGG4 neuropathy: pathophysiological insights, spectrum of clinical severity and response to treatment. Muscle Nerve 2018; 57 (05) 848-851
    CrossrefPubMedGoogle Scholar
  • 150 Querol L, Nogales-Gadea G, Rojas-Garcia R. , et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013; 73 (03) 370-380
    CrossrefPubMedGoogle Scholar
  • 151 Burnor E, Yang L, Zhou H. , et al. Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology 2018; 90 (01) e31-e38
    CrossrefPubMedGoogle Scholar
  • 152 Querol L, Rojas-García R, Diaz-Manera J. , et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015; 2 (05) e149
    CrossrefPubMedGoogle Scholar
  • 153 Gorson KC, van Schaik IN, Merkies ISJ. , et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15 (04) 326-333
    CrossrefPubMedGoogle Scholar
  • 154 Remenyi P, Masszi T, Borbenyi Z. , et al. CIDP cured by allogenic hematopoietic stem cell transplantation. Eur J Neurol 2007; 14 (08) e1-e2
    PubMedGoogle Scholar